Good morning. It's July 20.

Last week we covered the GLP-1 longevity debate - clinics selling Ozempic microdoses for aging, experts saying the evidence wasn't there yet.

This week: the evidence started showing up.

Researchers just published the first clinical data showing semaglutide - the active ingredient in Ozempic - may actually slow biological aging markers in humans. And the FDA just approved a major Alzheimer's drug for home self-injection - no infusion center required. Big week.

The rundown for this week:

Let's get to it. 👇

A 12-week intermittent fasting program produced weight loss that was still measurable a full year later - participants who ate within an 8-hour daily window maintained more weight loss at the 12-month mark than those who tried other approaches. The finding adds to the case that time-restricted eating produces durable metabolic changes, not just short-term results. ScienceDaily

The FDA approved lecanemab's subcutaneous autoinjector for at-home use on July 13 - patients with early Alzheimer's can now start and maintain treatment without visiting an infusion center. Real-world LEADER study data presented the next day at AAIC found 82.5% of patients stayed stable or improved over 17 months of treatment. PR Newswire

Finerenone slows kidney function decline in patients with chronic kidney disease who don't have diabetes - an international study found the drug reduces the risk of serious kidney and cardiovascular complications. Chronic kidney disease affects over 800 million people globally and accelerates biological aging; new treatment options matter well beyond nephrology. ScienceDaily

Combining a senolytic vaccine with mesenchymal stem cells may create a synergistic longevity effect - Immorta Bio research suggests the two approaches work better together than either does alone. Senolytics clear senescent cells - the damaged, inflammation-driving cells that linger in tissue and resist dying. Mesenchymal stem cells help restore the regenerative capacity those zombie cells have suppressed. Lifespan.io

Scientists identified a network of aging-related genes that could help existing approved drugs be repurposed for longevity - the approach was validated against 17 drugs already in longevity trials and 11 that extend lifespan in mice. The implication: the fastest path to a longevity drug may already be sitting in the FDA-approved pharmacopeia. MedicalXpress

Last week we debated whether GLP-1 drugs should be used for longevity. This week, a study gave that debate its first piece of actual human data.

Researchers found that semaglutide - the active ingredient in Ozempic and Wegovy - slowed biological aging markers in adults living with HIV, marking the first clinical evidence that the drug may influence how humans age at the molecular level.

The study, published in ScienceDaily on July 14, 2026, measured biological aging using epigenetic clocks - tools that estimate biological age by analyzing DNA methylation patterns, the chemical tags on DNA that change in predictable ways as cells age and experience stress. People living with HIV typically show accelerated biological aging compared to the general population, driven by chronic inflammation and the effects of the virus on immune function.

Semaglutide slowed the rate at which those aging markers were accumulating.

The science breakdown:

The critical caveat: This study was in adults with HIV - a population that ages faster than average and has a specific inflammatory profile. Whether semaglutide slows epigenetic aging in metabolically healthy people without HIV is a completely different question. The study does not answer that.

What it does do: establish for the first time that semaglutide can measurably affect biological aging markers in living humans. That's a meaningful data point. It's not permission to start microdosing Ozempic for longevity - last week's expert consensus on that still stands. But it opens a research question that is now worth pursuing properly, in larger and more diverse populations.

👉 ScienceDaily

Get up to 52% off Grüns Daily Greens and make daily nutrition effortless. Each serving delivers 60 ingredients, including 21 essential vitamins and minerals plus 6g of prebiotic fiber to help support energy, digestion, and immune health. Skip the hassle of pills and powders. These great-tasting gummies make it easy to stay consistent.

Designed for busy lifestyles, Grüns is portable, mess-free, and simple to take anywhere. It is also suitable for kids, making it a convenient way to support the whole family’s wellness routine. Build a habit you will actually stick to and feel good about every day.

Shop Up to 52% Off

ONTO Health, a physician-led fertility and longevity provider, announced on July 7 that it has acquired LEVY Health, a clinical decision support software company built for reproductive medicine. It's ONTO's first acquisition, and it came fast: the ink was barely dry on the company's $20 million Series A before it went shopping for infrastructure.

ONTO was founded by Dr. Roohi Jeelani, a double board-certified reproductive endocrinology and infertility specialist. The company's pitch treats fertility as an early marker of overall aging and long-term health, not an isolated concern - pairing personalized fertility care with proactive management of the rest of a patient's health span.

LEVY Health, co-founded by Caroline Mitterdorfer, Silvia Hecher, and Theresa Vilsmaier, builds the software providers use to flag endocrine disorders and speed up the diagnostic workups that come before fertility treatment. Instead of licensing that technology indefinitely, ONTO now owns it outright.

Why this deal matters:

This is part of a pattern worth watching in longevity: the market is still young and fragmented, full of single-purpose diagnostic and software startups. As larger platforms raise Series A and B rounds, expect more of that capital to go toward buying up the smaller point-solution tools rather than building competing ones from scratch - vertical integration instead of vendor relationships.

👉 PR Newswire | Femtech Insider

For that you get a single blood draw covering 100+ biomarkers - hormones, thyroid, metabolic function, inflammation, cardiovascular markers, nutrients, liver, kidney, and immune health - plus a personalized action plan, and 24/7 access to a care team, and a supplement marketplace with members-only pricing.

Testing happens at 2,000+ labs across the US, or you can book a home visit. HSA and FSA eligible.

Results land in your dashboard within about a week, organized into 17 health scores, a biological age estimate, and a clear breakdown of what to do next. You can sync your wearables, upload old lab PDFs, and track your trends over time.

If you've been optimizing sleep, training, and nutrition but have never actually looked under the hood - this is the missing piece.

👉 Get Superpower - use code STAYIN20OFF for $20 off your first purchase

(This section contains an affiliate link - if you buy through it, we may earn a commission at no extra cost to you.)

We've known for decades that the Mediterranean diet is good for you.

Heart health, cognitive protection, lower cancer rates, longer life - the epidemiological evidence is overwhelming. What's been harder to explain is exactly why, at the molecular level.

New research published July 17 points to an unexpected answer: mitochondrially derived peptides, or MDPs.

Mitochondria are the energy-generating organelles inside your cells - the "powerhouses" you've heard about since high school biology. It turns out they also produce tiny proteins called MDPs that act as signaling molecules, traveling through the body and influencing everything from inflammation to brain function to cardiovascular health.

Older adults who followed the Mediterranean diet most closely showed patterns suggesting greater activation of these MDPs - including ones associated with heart and brain protection.

Why is this a meaningful finding? Because it provides a plausible molecular mechanism that ties dietary patterns to cellular aging biology. MDPs are a relatively young area of research, but the early evidence suggests they may be one of the key molecular messengers through which lifestyle choices - particularly diet - communicate with your cells' longevity machinery.

The practical upshot is the same as it's always been: more olive oil, fish, vegetables, legumes, and whole grains. Less processed food. But now there's a specific molecular pathway to point to when someone asks why.

👉 ScienceDaily

This week's From the Clinic covered the first evidence that a drug can slow biological aging markers. This book asks whether you can do it without drugs at all - and shows a clinical trial to back up the claim.

Dr. Kara Fitzgerald ran a randomized controlled trial where participants followed an 8-week program centered on a methylation-support diet - a way of eating designed to optimize the biochemical processes that regulate gene expression and influence epigenetic age. The results, published in the peer-reviewed journal Aging: biological age reduced by an average of 3.23 years in the intervention group versus 0.07 years in the control group.

Methylation is the chemical process your cells use to switch genes on and off. Specific nutrients - found in things like dark leafy greens, eggs, liver, beets, and sunflower seeds - provide the raw materials for optimal methylation. The diet is close to Mediterranean in character.

The book translates the trial's framework into something practical. If you've spent time thinking about epigenetic clocks and biological age testing, this is where the actionable diet science lives.

👉 Get Younger You

Your Mouth Is A Good Overall Health Indicator 👇

Ad slots are filling up fast. To promote your longevity / biohacking product to our niche audience, see the media kit and get in touch with Sebastian at [email protected]